Treating comorbid depression and anxiety

Journal of Family Practice

Volumn 43, Issue 6 SUPPL., 1996, Pages

  Kuzel, Russel J ^a,b  

^a Dakota Clinic at West Acres ^*

^b Dakota Clinic   (United States)

Author keywords

anxiety; comorbidity; Depression; drug therapy

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AKATHISIA; ANXIETY NEUROSIS; ARTICLE; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; HUMAN; PSYCHIATRIC DIAGNOSIS; PSYCHOPATHY; RISK ASSESSMENT; SEXUAL DYSFUNCTION; TREATMENT PLANNING; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; HUMANS; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS;

EID: 0030469377     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993; 54(suppl 1):33-8.
2. DSM-IV. Appendix B. Criteria sets and axes provided for further study. Diagnostic and statistical manual of mental disorder. 4th ed. Washington, DC: American Psychiatric Association, 1994:703-71.
3. Hiller W, Zaudig M, Monbour M. ICDL - The International Diagnostic Checklists for ICD-IO and DSM-IV. Bern, Switzerland: Huber and Hogrefe. In press.
4. Clayton PJ. Anxious depression: a reemerging subtype of depression. In: Racagni G, Smeraldi E, eds. Anxious depression: assessment and treatment, New York: Raven Press, 1987:1-5.
5. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983; 44(8, sec 2):8-11.
6. Barrett JE, Barrett JA, Oxman TE, Gerber PD. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988; 45:1100-6.
7. Murphy J, Oliver D, Sobol A, et al. Diagnosis and outcome: depression and anxiety in a general population. Psychol Med 1986; 16:117-26.
8. Johnson J, Weissman MM, Klerman GL. Panic disorder, comorbidity and suicide attempts. Arch Gen Psychiatry 1990; 47(9):805-8.
9. Blazer D, Swartz M, Woodbury M, Manton KG, Hughes D, George LK. Depressive symptoms and depressive diagnoses in a community population. Arch Gen Psychiatry 1988; 45:1078-84.
10. Clancy J, Noyes R Jr, Hoenk PR, Slymen DJ. Secondary depression and anxiety neurosis. J Nerv Ment Dis 1978; 166:846-50.
11. Van Valkenburg C, Akiskal HS, Puzantian V, Rosenthal T. Anxious depression: clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord 1984; 6:67-82.
12. Grunhaus L, Harel Y, Krugler T, Pande AC, Haskett RE Major depressive disorder and panic disorder effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol 1988; 11:454-61.
13. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia, I: frequency, severity, and response to treatment. Arch Gen Psychiatry 1988; 45:437-43.
14. Katon W, Roy-Byrne P. Mixed anxiety and depression. J Abnorm Psychol 1991; 100:337-45.
15. Fawcett J. Predictors of early suicide: identification and appropriate intervention. J Clin Psychiatry 1988; 49(suppl 10):7-8.
16. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990; 147:1189-94.
17. Cullberg J, Wasserman D, Stefansson CG. Who commits suicide after a suicide attempt? An 8 to 10 year follow up in a suburban catchment area Acta Psychiatr Scand 1988; 77:598-603.
18. Nielsen B, Wang AG, Bille-Brahe U. Attempted suicide in Denmark, IV: a five-year follow up. Acta Psychiatr Scand 1990; 81:250-4.
19. Suokas J, Lönnqvist J. Outcome of attempted suicide and psychiatric consultation: risk factors and suicide mortality during a five-year follow-up. Acta Psychiatr Scand 1991; 84:545-9.
20. Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56(suppl 6):22-9.
21. McGlynn TJ, Metcalf HL, eds. Diagnosis and treatment of anxiety disorders: a physician's handbook. Washington, DC: American Psychiatric Press, 1989:8-11.
22. Preskorn SH, Fast GA. Beyond signs and symptoms: the case against a mixed anxiety and depression category. J Clin Psychiatry 1993; 54(suppl 1):24-32.
23. Aronson TA. A naturalistic study of imipramine in panic disorder and agoraphobia Am J Psychiatry 1987; 144:1014-9.
24. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50:44-50.
25. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56(suppl 6):37-42.
26. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychiatry 1995; 13:2-12.
27. Sheehan D, Dunbar GC, Fuell DL The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 1992; 28:139-43.
28. Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987; 144:664-5.
29. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988; 49:100-4.
30. Zubenko GS, Cohen BM, Lipinski JF Jr. Antidepressant-related akathisia J Clin Psychopharmacol 1987; 7:254-7.
31. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 67(suppl 6A):24-33.
32. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994; 55(suppl 12):3-15.
33. Litovitz T, Clark LR, Soloway RA. 1993 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994; 12:546-54.
34. Boyer WF, Feighner JP Other potential indications for selective serotonin re-uptake inhibitors. In: Feighner JP, Boyer WF, eds. Selective serotonin re-uptake inhibitors. West Sussex, England: John Wiley and Sons, 1991:119-45.
35. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55(2):50-9.
36. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28:1359-69.
37. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55:406-13.
38. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25:191-201.
39. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994; 55:394-400.
40. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992; 12:328-33.
41. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52:491-3.
42. Fleischhacker WW. Propranolol for fluoxetine-induced akathisia. Biol Psychol 1991; 30:531-2.
43. McElroy SL, Keck PE Jr, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995; 56(suppl 2):49-55.
44. DeWilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S. A double-blind, comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87:141-5.
45. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11:930-57.
46. DeVane CL Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97(suppl 6A):13S-23S.
47. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269:1513-8.
48. Solvay Pharmaceuticals. Luvox prescribing information. Marietta, Ga: Solvay Pharmaceuticals, 1995.
49. Crewe HK, Leonard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-5.
50. Aranow RB, Hudson JI, Pope HG Jr, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989; 146:911-3.
51. Barros J, Asnis G. An interaction of sertraline and desipramine [letter]. Am J Psychiatry 1993; 150:1751.
52. Bell IR, Cole JO. Fluoxetine induced elevation of desipramine level and exacerbation of geriatric nonpsychotic depression [letter]. J Clin Psychopharmacol 1988; 8:447-8.
53. Goodnick PJ. Influence of fluoxetine on plasma levels of desipramine [letter]. Am J Psychiatry 1989; 146:552.
54. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993; 150:1125-6.
55. Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990; 147:532.
56. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. Does sertraline inhibit CYP2D6 after chronic dosing? [abstract]. Clin Pharmacol Ther 1995; 57:151.
57. Vaughan DA Interaction of fluoxetine with tricyclic antidepressants [letter]. Am J Psychiatry 1988; 145:1478.
58. Zussman BD, Davie CC, Fowles SE, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 1995; 39:550-1.
59. Physician drug and diagnosis audit Newtown, Pa: Scott-Levin Associates, 1994.
60. Zisook S, Braff DL, Click MA Monoamine oxidase inhibitors in the treatment of atypical depression. J Clin Psychopharmacol 1985; 5:131-7.
61. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine versus atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290-300.
62. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179:366-70.
63. Cesura AM, Pletscher A The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992; 38:171-297.
64. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine v imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984; 41:669-77.
65. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45:129-37.
66. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990; 47:935-41.
67. Fawcett J. Targeting treatment in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990;51(suppl 11):40-3.
68. Michels R, Marzuk PM. Progress in psychiatry: second of two parts. N Engl J Med 1993; 329:628-38.
69. Elison MS. Azapirones: clinical uses of serotonin partial ago-niste. Fam Pract Recert 1989; 11:1-7.
70. Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991; 52:34-8.
71. Schweizer E, Amsterdam J, Rickels K, Kaplan M, Droba M. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986; 22:183-5.
72. Baughman OL III. Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient J Fam Pract 1994; 39:373-8.
73. Beck AT. Cognitive approaches to panic disorder: theory and therapy. In: Rachman S, Maser J, eds. Panic: psychological perspectives. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988:23-38.
74. Shear MK, Schulberg HC. Anxiety disorders in primary care. Bull Benninger Clin 1995; 59(2 suppl A):A73-85.
75. Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992; 14:237-47.